Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARCT 
Arcturus Therapeutics Holdings Inc (ARCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ARCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $68.9
1 Year Target Price $68.9
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.93% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 470.32M USD | Price to earnings Ratio - | 1Y Target Price 68.9 |
Price to earnings Ratio - | 1Y Target Price 68.9 | ||
Volume (30-day avg) 11 | Beta 2.39 | 52 Weeks Range 8.04 - 25.88 | Updated Date 09/14/2025 |
52 Weeks Range 8.04 - 25.88 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.27% | Operating Margin (TTM) -41.04% |
Management Effectiveness
Return on Assets (TTM) -13% | Return on Equity (TTM) -24.58% |
Valuation
Trailing PE - | Forward PE 2.48 | Enterprise Value 300813442 | Price to Sales(TTM) 3.85 |
Enterprise Value 300813442 | Price to Sales(TTM) 3.85 | ||
Enterprise Value to Revenue 2.74 | Enterprise Value to EBITDA -25.67 | Shares Outstanding 27154500 | Shares Floating 25017468 |
Shares Outstanding 27154500 | Shares Floating 25017468 | ||
Percent Insiders 7.88 | Percent Institutions 89.26 |
Upturn AI SWOT
Arcturus Therapeutics Holdings Inc
Company Overview
History and Background
Arcturus Therapeutics Holdings Inc. was founded in 2013. It is a biotechnology company focusing on messenger RNA (mRNA) medicines.
Core Business Areas
- mRNA Medicines: Development of mRNA-based therapeutics for various diseases, including vaccines and gene therapies.
- LUNAR Platform: Proprietary lipid nanoparticle (LNP) delivery platform for mRNA therapeutics.
- Nucleotide Chemistry: Developing novel nucleic acid chemistries to improve the stability and efficacy of mRNA.
Leadership and Structure
Joseph E. Payne is the President & CEO. The company has a board of directors and various research and development teams.
Top Products and Market Share
Key Offerings
- ARCT-154 (COVID-19 vaccine): A next-generation, self-amplifying mRNA COVID-19 vaccine. Arcturus is still seeking regulatory approval, therefore there is no current market share. Competitors include Pfizer/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX).
- ARCALIS (Ornithine Transcarbamylase (OTC) Deficiency treatment): mRNA-based therapy for OTC deficiency, a rare genetic liver disorder. Currently in clinical development, so market share is not available. Potential competitors would be companies developing gene therapies or other novel treatments for OTC deficiency.
Market Dynamics
Industry Overview
The mRNA therapeutics market is rapidly growing, driven by the success of mRNA COVID-19 vaccines. It includes applications in vaccines, gene therapy, and protein replacement therapy.
Positioning
Arcturus aims to be a leader in mRNA medicines through its LUNAR delivery platform and self-amplifying mRNA technology. Its competitive advantages include novel chemistries and formulations.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach hundreds of billions of dollars in the coming years. Arcturus is positioned to capture a portion of this TAM through its pipeline and technology platform.
Upturn SWOT Analysis
Strengths
- Proprietary LUNAR delivery platform
- Self-amplifying mRNA technology
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on partnerships for funding and development
- Clinical trial risks and regulatory hurdles
- Limited commercialized products
- Smaller market capitalization compared to larger competitors
Opportunities
- Expansion of mRNA technology into new therapeutic areas
- Strategic partnerships and collaborations
- Positive clinical trial results
- Increased government funding for mRNA research
Threats
- Competition from larger pharmaceutical companies
- Patent challenges
- Adverse events in clinical trials
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- NVAX
- CURE
Competitive Landscape
Arcturus has a competitive advantage in its LUNAR delivery platform and self-amplifying mRNA. However, it faces strong competition from larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Arcturus has experienced significant growth in research and development activities, driven by its mRNA technology and partnerships.
Future Projections: Analysts project continued revenue growth for Arcturus, driven by clinical trial progress and potential product approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for ARCT-154 and ARCALIS, and expanding its LUNAR delivery platform.
Summary
Arcturus Therapeutics is a biotechnology company focused on mRNA medicines with a promising LUNAR delivery platform and self-amplifying mRNA technology. While it has strengths in its technology and pipeline, it faces challenges related to funding, clinical trial risks, and competition. Future success depends on advancing its clinical programs and securing strategic partnerships. Arcturus is focused on pushing the boundaries on new technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcturus Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-16 | Founder, President, CEO & Director Mr. Joseph E. Payne M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 174 | Website https://arcturusrx.com |
Full time employees 174 | Website https://arcturusrx.com | ||
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.